

SPECIALTY GUIDELINE MANAGEMENT

Cetrotide (cetorelix acetate) ganirelix acetate

POLICY

A. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered covered benefits provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Cetrotide is indicated for the inhibition of premature LH (leutinizing hormone) surges in women undergoing controlled ovarian stimulation.

Ganirelix is indicated for the inhibition of premature LH (leutinizing hormone) surges in women undergoing controlled ovarian hyperstimulation.

All other indications are considered experimental/investigational and are not covered benefits.

B. REQUIRED DOCUMENTATION

The following information is necessary to initiate the prior authorization review:
Documentation of the type of procedure to be performed

C. CRITERIA FOR APPROVAL

1. **Prevention Of LH Surges During Ovarian Stimulation For Ovulation Induction Or As Part Of An Assisted Reproductive Technology Procedure**
 - a. Authorization of 12 months may be granted for female members prescribed Cetrotide or ganirelix for the inhibition of premature LH surges who are undergoing ovarian stimulation with follitropins and/or menotropins for ovulation induction or as part of an assisted reproductive technology procedure

D. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet ALL initial authorization criteria.

E. DOSAGE AND ADMINISTRATION

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

The following dosing limits apply:
4 mg per month

REFERENCES

1. Cetrotide [package insert]. Rockland, MA: EMD Serono; January 2014.
2. Ganirelix [package insert]. Whitehouse Station, NJ: Merck & Co. Inc.; December 2013.
3. Bakas P, Konidaris S, Liapis A, et al. Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation. *Fertility & Sterility*. 2011;95(6):2024-28.

Cetrotide-Ganirelix SGM P2015

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst and BlueChoice members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. are both independent licensees of the Blue Cross and Blue Shield Association. The Blue Cross and Blue Shield Names and Symbols are registered trademarks of the Blue Cross and Blue Shield Association. © Registered trademark of CareFirst of Maryland, Inc.